|
業務類別
|
-- |
|
業務概覽
|
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada. |
| 公司地址
| 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668 |
| 電話號碼
| +81 332782306 |
| 傳真號碼
| +81 332782268 |
| 公司網頁
| https://www.takeda.com |
| 員工數量
| 49281 |
| Mr. Gabriele Ricci |
Chief Data and Technology Officer |
-- |
25/06/2025 |
| Ms. Akiko Amakawa |
Corporate Strategy Officer and Chief Executive Officer Chief of Staff |
-- |
25/06/2025 |
| Ms. Lauren Duprey |
Chief Human Resources Officer |
-- |
25/06/2025 |
| Ms. Takako Ohyabu |
Chief Global Corporate Affairs and Sustainability Officer |
-- |
25/06/2025 |
| Dr. Thomas Wozniewski, PhD |
Global Manufacturing and Supply Officer |
-- |
25/06/2025 |
| Ms. Ramona A. Sequeira |
President, Global Portfolio Division |
-- |
25/06/2025 |
| Mr. Giles Platford |
President, Plasma-Derived Therapies Business Unit |
-- |
25/06/2025 |
| Ms. Mwana Lugogo |
Chief Ethics and Compliance Officer |
-- |
25/06/2025 |
| Mr. Milano Furuta |
Director and Chief Financial Officer |
美元 88.00M |
25/06/2025 |
| Ms. Teresa Marie Bitetti |
President, Global Oncology Business Unit |
-- |
25/06/2025 |
| Mr. Marcello Agosti |
Global Business Development Officer |
-- |
25/06/2025 |
| Mr. Christophe Weber |
Director, President and Chief Executive Officer; Head of Global Business of Takeda Pharmaceuticals U.S.A., Inc. |
日圓 251.00M |
25/06/2025 |
| Ms. Elaine Shannon |
Global Quality Officer |
-- |
25/06/2025 |
| Ms. Asuka Miyabashira |
President, Japan Pharma Business Unit |
-- |
25/06/2025 |
| Ms. Julie Kim |
President, U.S. Business Unit and U.S. Country Head |
-- |
25/06/2025 |
| Mr. Andrew S. Plump, M.D. |
Director and President, Research and Development |
日圓 12.00M |
25/06/2025 |
|
|
| Mr. Masami Iijima |
Chairman of the Board |
25/06/2025 |
| Ms. Miki Tsusaka |
Independent Director |
25/06/2025 |
| Ms. Kimberly A. Reed |
Independent Director |
25/06/2025 |
| Mr. Milano Furuta |
Director and Chief Financial Officer |
25/06/2025 |
| Mr. Koji Hatsukawa |
Independent Director |
25/06/2025 |
| Mr. Christophe Weber |
Director, President and Chief Executive Officer; Head of Global Business of Takeda Pharmaceuticals U.S.A., Inc. |
25/06/2025 |
| Mr. Michel Orsinger |
Independent Director |
25/06/2025 |
| Ms. Emiko Higashi |
Independent Director |
25/06/2025 |
| Mr. Yoshiaki Fujimori |
Independent Director |
25/06/2025 |
| Dr. Steven Gillis, Pd.D |
Independent Director |
25/06/2025 |
| Dr. John M. Maraganore,PhD |
Independent Director |
25/06/2025 |
| Mr. Jean-Luc Butel |
Independent Director |
25/06/2025 |
| Mr. Ian T. Clark |
Independent Director |
25/06/2025 |
| Mr. Andrew S. Plump, M.D. |
Director and President, Research and Development |
25/06/2025 |
|
|
|
|
